Perception About Benefits and Risks Related to Combined Hormonal Contraceptives Use in Women with Lynch Syndrome

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Jun 26

PMID 38920120

Authors

Fabio Barra

Umberto Perrone

Simone Ferrero

Stefano Bogliolo

Silvia Ottonello

Claudio Gustavino

Angela Iasci

Giovanni Grandi

Alessandra Pulliero

Maria Grazia Centurioni

Alberto Izzotti

Affiliations

Soon will be listed here.

Abstract

Objective: Lynch syndrome (LS) is a hereditary condition associated with an increased risk of colorectal and endometrial cancer. This study aimed to assess the knowledge, attitudes, and beliefs of women with LS regarding combined hormonal contraceptive (CHC) use compared to a control group of healthy women.

Methods: Pre-menopausal women with LS ( = 43) and an age-matched control group of healthy women ( = 128) participated in this prospective, cross-sectional study (NCT05909410). Participants completed an electronic questionnaire evaluating perceptions of CHC use and its impact on various cancers, medical conditions, and symptoms. Statistical analysis compared responses between the two groups, with reported -values.

Results: Women with LS were less likely to use CHCs compared to the control group ( = 0.03) and had a more negative perception of CHCs' impact on colorectal cancer ( = 0.023) and endometrial cancer ( = 0.028). Limited knowledge was observed in both groups regarding the protective effects of CHCs against colorectal and ovarian cancer. Perceptions of CHC use and its impact on symptoms and chronic diseases did not significantly differ between the groups ( > 0.05). CHC use was not associated with greater awareness of the protective effect against colorectal ( = 0.89) and endometrial cancer ( = 0.47), but it was associated with a desire for contraception (OR 21.25; 95% CI 1.16 to 388.21; = 0.039).

Conclusion: This study highlights contrasting perceptions of CHCs and their implications in oncology between women with LS and healthy women. Tailored counselling and support strategies are crucial for empowering women with LS to make informed decisions about their gynaecologic health.

References

Iversen L, Fielding S, Lidegaard O, Hannaford P . Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: A retrospective cohort study of Danish women. Contraception. 2020; 102(3):152-158. DOI: 10.1016/j.contraception.2020.06.008. View

Weiss J, Gupta S, Burke C, Axell L, Chen L, Chung D . NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. J Natl Compr Canc Netw. 2021; 19(10):1122-1132. DOI: 10.1164/jnccn.2021.0048. View

Morch L, Hannaford P, Lidegaard O . Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2018; 378(13):1265-1266. DOI: 10.1056/NEJMc1800054. View

Diergaarde B, Braam H, Vasen H, Nagengast F, van Muijen G, Kok F . Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol. 2007; 5(6):736-42. DOI: 10.1016/j.cgh.2007.02.019. View

Lu K, Loose D, Yates M, Nogueras-Gonzalez G, Munsell M, Chen L . Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013; 6(8):774-81. PMC: 3737517. DOI: 10.1158/1940-6207.CAPR-13-0020. View

Havrilesky L, Moorman P, Lowery W, Gierisch J, Coeytaux R, Urrutia R . Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122(1):139-147. DOI: 10.1097/AOG.0b013e318291c235. View

Sun C, Meyer L, Daniels M, Bodurka D, Nebgen D, Burton-Chase A . Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol. 2019; 152(3):514-521. PMC: 6422049. DOI: 10.1016/j.ygyno.2018.11.027. View

Grandi G, Del Savio M, Boggio Sola V, Monari F, Melotti C, Facchinetti F . Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?. Ann Med. 2021; 53(1):908-915. PMC: 8205098. DOI: 10.1080/07853890.2021.1938662. View

Gallo M, Lopez L, Grimes D, Schulz K, Helmerhorst F . Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2006; (1):CD003987. DOI: 10.1002/14651858.CD003987.pub2. View

10.

Grandi G, Boggio Sola V, Cortesi L, Toss A, Giuliani G, Del Savio M . BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study. Psychooncology. 2021; 30(10):1711-1719. PMC: 8518789. DOI: 10.1002/pon.5714. View

11.

Kershaw V, Hickey I, Wyld L, Jha S . The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021; 265:7-17. DOI: 10.1016/j.ejogrb.2021.08.001. View

12.

Dominguez-Valentin M, Sampson J, Seppala T, Ten Broeke S, Plazzer J, Nakken S . Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2019; 22(1):15-25. PMC: 7371626. DOI: 10.1038/s41436-019-0596-9. View

13.

De Leo V, Musacchio M, Cappelli V, Piomboni P, Morgante G . Hormonal contraceptives: pharmacology tailored to women's health. Hum Reprod Update. 2016; 22(5):634-46. DOI: 10.1093/humupd/dmw016. View

14.

Teal S, Edelman A . Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA. 2021; 326(24):2507-2518. DOI: 10.1001/jama.2021.21392. View

15.

Wang G, Kuppermann M, Kim B, Phillips K, Ladabaum U . Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract. 2012; 8(3 Suppl):e24s-30s. PMC: 3348599. DOI: 10.1200/JOP.2011.000535. View

16.

Nappi R, Pellegrinelli A, Campolo F, Lanzo G, Santamaria V, Suragna A . Effects of combined hormonal contraception on health and wellbeing: women's knowledge in northern Italy. Eur J Contracept Reprod Health Care. 2014; 20(1):36-46. DOI: 10.3109/13625187.2014.961598. View

17.

Skrivankova V, Richmond R, Woolf B, Yarmolinsky J, Davies N, Swanson S . Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021; 326(16):1614-1621. DOI: 10.1001/jama.2021.18236. View

18.

Davidson B, Moorman P . Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer. Expert Opin Drug Saf. 2014; 13(10):1375-82. DOI: 10.1517/14740338.2014.951327. View

19.

Dashti S, Chau R, Ait Ouakrim D, Buchanan D, Clendenning M, Young J . Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome. JAMA. 2015; 314(1):61-71. PMC: 4688894. DOI: 10.1001/jama.2015.6789. View

20.

de Bastos M, Stegeman B, Rosendaal F, van Hylckama Vlieg A, Helmerhorst F, Stijnen T . Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014; (3):CD010813. PMC: 10637279. DOI: 10.1002/14651858.CD010813.pub2. View